View Filing Data

Document and Entity Information	3 Months Ended
Mar. 31, 2016
Document And Entity Information [Abstract]
Document Type	POS AM
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Trading Symbol	TPIV
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$ 5,721,801	$ 6,576,564	$ 141,944
Prepaid expenses and deposits	37,632	68,803	82,504
Total Current Assets	5,759,433	6,645,367	224,448
Current Liabilities
Accounts payable and accrued liabilities	1,454,913	967,358	693,362
Research agreement obligations	492,365	492,365	492,365
Derivative liability - warrants	29,489,000	26,493,000	9,415
Promissory notes	5,000	30,000	29,942
Promissory note, related party	23,000	23,000	23,000
Total Current Liabilities	31,464,278	28,005,723	1,248,084
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock
Common stock	70,991	70,551	20,319
Additional paid-in capital	112,482,330	112,077,520	85,265,776
Accumulated deficit	(138,258,166)	(133,508,427)	(86,309,731)
Accumulated other comprehensive loss		0	0
Total Stockholders' Deficit	(25,704,845)	(21,360,356)	(1,023,636)
Total liabilities and stockholder's deficit	5,759,433	6,645,367	224,448
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000	5,000,000
Preferred stock outstanding		0
Common stock shares par value	$ 0.001	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000	500,000,000
Common stock shares issued	70,990,763	70,550,763	20,318,815
Common stock shares outstanding	70,990,763	70,550,763	20,318,815
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000	1,250,000
Preferred stock issued	0	0	0
Preferred stock outstanding	0	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000	1,500,000
Preferred stock issued	0	0	0
Preferred stock outstanding	0	0	0

Condensed Consolidated Statements of Operations Loss - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Operating expenses:
General and administrative	$ 767,988	$ 418,786	$ 4,447,781	$ 3,181,927
Research and development	985,751	609,378	1,711,177	189,000
Loss from Operations	(1,753,739)	(1,028,164)	(6,158,958)	(3,370,927)
Other Income (Expense)
Foreign exchange (loss) gain			775	(52,976)
Changes in fair value of derivative liabilities	(2,996,000)	327,440	(27,872,585)	581
Accretion of discount on convertible notes				(492,296)
Interest and financing charges			(10,925)	(83,247)
Loss on extinguishment of debt				(26,884,231)
Loss on settlement agreement			(24,697)
Net Loss	$ (4,749,739)	$ (700,724)	(34,066,390)	(30,883,096)
Other comprehensive income
Foreign exchange translation adjustment				58,334
TOTAL COMPREHENSIVE LOSS			$ (34,066,390)	$ (30,824,762)
Basic and Diluted Net Loss per Share	$ (0.07)	$ (0.03)	$ (0.78)	$ (2.00)
Weighted Average Number of Common Shares Outstanding	70,593,236	27,611,255	43,947,067	15,465,213

Condensed Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance, Amount at Dec. 31, 2013	$ (8,768,003)	$ 1,466	$ 46,715,500	$ (55,426,635)	$ (58,334)
Beginning Balance, Share at Dec. 31, 2013		1,465,712
Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock,Amount	30,951,078	$ 14,049	30,937,029
Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock,Share		14,048,701
Conversion of accounts payable to common stock, Amount	4,349,428	$ 1,836	4,347,592
Conversion of accounts payable to common stock, Share		1,836,361
Private placement (net of finders' fee) Amount	1,877,500	$ 2,157	1,875,343
Private placement (net of finders' fee) share		2,157,042
Foreign exchange translation adjustment	58,334				$ 58,334
Stock- based compensation, Amount	1,391,123	$ 811	1,390,312
Stock- based compensation, Share		811,000
Net loss	(30,883,096)			(30,883,096)
Ending Balance, Amount at Dec. 31, 2014	(1,023,636)	$ 20,319	85,265,776	(86,309,731)
Ending Balance, Share at Dec. 31, 2014		20,318,816
Accounts payable settled in shares, Amount	21,913	$ 118	21,795
Accounts payable settled in shares, Share		118,450
Private placement (net of finders' fee) Amount	2,326,015	$ 12,321	2,313,694
Private placement (net of finders' fee) share		12,363,447
Fair value of warrants recognized as derivative liabilities in January and March 2015 Financing	(9,313,000)		(2,313,694)	(6,999,306)
Fair value of warrants issued on May 28, 2015	(6,133,000)			(6,133,000)
Exercise of warrants, Amount	9,219,998	$ 37,122	9,182,876
Exercise of warrants, Share		37,079,990
Reclassification of Derivative Warrant Liabilities to Equity at exercise date	16,835,000		16,835,000
Finders' fee on exercise of warrants	(767,995)		(767,995)
Shares issued in settlement, Amount	26,473	$ 50	26,423
Shares issued in settlement, Share		49,950
Stock- based compensation, Amount	1,514,266	$ 621	1,513,645
Stock- based compensation, Share		620,110
Net loss	(34,066,390)			(34,066,390)
Ending Balance, Amount at Dec. 31, 2015	(21,360,356)	$ 70,551	112,077,520	(133,508,427)
Ending Balance, Share at Dec. 31, 2015		70,550,763
Stock- based compensation, Amount	405,250	$ 440	404,810
Stock- based compensation, Share		440,000
Net loss	(4,749,739)			(4,749,739)
Ending Balance, Amount at Mar. 31, 2016	$ (25,704,845)	$ 70,991	$ 112,482,330	$ (138,258,166)
Ending Balance, Share at Mar. 31, 2016		70,990,763

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (4,749,739)	$ (700,724)	$ (34,066,390)	$ (30,883,096)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	2,996,000	(327,440)	27,872,585	(581)
Loss on extinguishment of debt				26,884,231
Loss on settlement agreement			24,697
Accretion of discount on convertible notes				492,296
Non-cash interest and finance charges			10,925	83,247
Stock based compensation	214,250	3,750	1,705,067	1,391,123
Foreign exchange loss				58,334
Changes in operating assets and liabilities:
Prepaid expenses and deposits	31,171		13,701	(67,500)
Accounts payable and accrued liabilities	678,555	9,961	96,018	(145,199)
NET CASH USED IN OPERATING ACTIVITIES	(829,763)	(1,014,453)	(4,343,397)	(2,187,145)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of finders' fee		2,326,014	2,326,015	1,877,500
Convertible notes issuance				418,000
Proceeds from exercise of warrants			9,219,998
Finders' fee on exercise of warrants			(767,996)
Repayment of promissory note	(25,000)			(15,000)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(25,000)	2,326,014	10,778,017	2,280,500
(DECREASE) INCREASE IN CASH	(854,763)	1,311,561	6,434,620	93,355
CASH, BEGINNING OF PERIOD	6,576,564	141,944	141,944	48,589
CASH, END OF PERIOD	5,721,801	1,453,505	6,576,564	141,944
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock			22,000	2,415,000
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation	$ 191,000
Fair value of issuance of warrants in January and March 2015 financing		$ 9,313,000	9,313,000
Issuance of additional warrants in May 28, 2015 transaction			6,133,000
Reclassification of Derivative Warrant Liabilities to Equity at exercise date			$ 16,835,000
Conversion of debt obligations into common stock:
Accrued interest				525,000
Convertible notes payable				4,116,000
Loans payable, related party				42,000
Promissory notes, related party				210,000
Due to related parties				369,000
Fair value derivative liability - conversion option at conversion				$ 708,000

Nature of Operations

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

NOTE 1: NATURE OF OPERATIONS

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

NOTE 1:

NATURE OF OPERATIONS

A Phase I study at the Mayo Clinic, Rochester, MN, evaluating the safety and immune responses of a set of proprietary HER2/neu+ antigens has been successfully completed and the results led to the decision to proceed with Phase II clinical studies in 2016.

A separate Phase I study has also been conducted at Mayo Foundation (“Mayo”) in Ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to Ovarian and Triple Negative Breast Cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications. This study has been successfully completed and the results led to the decision to proceed with multiple Phase II studies in 2016.

In addition, enhancing the visibility of cancer or infected cells to a patient’s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune’s PolyStart nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient’s cancer cells.

These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at December 31, 2015, the Company had a working capital deficiency and has incurred significant losses since inception in the development of its business. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund clinical trials, ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and ultimately on generating future profitable operations. Planned expenditures relating to current and future clinical trials of the Company’s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.

Management is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation. Management’s plans are intended to return the Company to financial stability and improve continuing operations. The Company is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet immediate working capital requirements.

Historically the Company has raised capital through issuances of various financial instruments and the Company recently completed significant restructuring of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company over the next twelve months.

There is no certainty that the Company will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.

Significant Accounting Policies

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2016.

Recent accounting pronouncement

Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this standard are effective for the Company’s annual year and first fiscal quarter beginning on January 1, 2017 with early adoption permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures.

NOTE 2:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

These financial statements include the accounts of the Company and its wholly-owned subsidiary GeneMax Pharmaceuticals Inc. (“GPI”). All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates

Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock based transactions, the fair value of the components of the derivative liabilities - warrants and accrued liabilities.

Fair Value Measurements

The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

•

Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

•

Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.

The fair values of cash, accounts payable, and other current monetary liabilities approximate their carrying values due to the immediate or short-term maturity of these financial instruments. The Company’s operations and financing activities are conducted primarily in United States dollars, and as a result the Company is not subject to significant exposure to market risks from changes in foreign currency rates. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from assets and liabilities classified as financial instruments.

Prior Period Reclassifications

Certain prior period amounts that were combined in the December 31, 2014 consolidated financial statements have been reclassified for comparability with the December 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.

Stock-Based Compensation

Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.

Research and Development Costs

The Company has acquired development and marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may not have alternate future uses and therefore, have been expensed as incurred as research and development costs. The Company spent $1,711,000 on research and development in the year ended December 31, 2015 compared to $189,000 during the prior fiscal year.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances against deferred tax assets.

Derivative Liability

The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Management must determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. This exercise affects the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain contingently puttable cash settlement.

Loss per Common Share

Basic loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. If applicable, diluted earnings per share reflect the potential dilution of securities that could share in the earnings (loss) of the Company. The common shares potentially issuable on conversion of outstanding convertible debentures, warrants and stock options are anti-dilutive and have not been included in the calculation.

Recently Issued Accounting Pronouncements

Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.

Derivative Liability - Warrants and Derivative Liability - Conversion Option

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Text Block [Abstract]

Derivative Liability - Warrants and Derivative Liability - Conversion Option

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended 2016 and 2015 is as follows:


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2016			For the Quarter Ending March 31, 2015
Exercise price	$	0.70		$	0.98
Contractual term (years)		4.00			4.00
Volatility (annual)		150.00	%		158.00	%
Risk-free rate		1.05	%		1.00	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of March 31, 2016
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	29,489,000		—		—	$	29,489,000	$	29,489,000

Total	$	29,489,000		—		—	$	29,489,000	$	29,489,000


	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		—		—	$	26,493,000	$	26,493,000

Total	$	26,493,000		—		—	$	26,493,000	$	26,493,000

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2016.

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2016:


	Derivative liability –warrants
Balance – January 1, 2016	$	26,493,000
Change in fair value of warrant liability		2,996,000

Balance – March 31, 2016	$	29,489,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

NOTE 5:

DERIVATIVE LIABILITY


Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Year Ending December 31, 2015			For the Year Ending December 31, 2014
Strike price	$	0.74		$	10.70
Volatility (annual)		155	%		166	%
Risk-free rate		1.8	%		1.00	%
Contractual term (years)		4.2			2. 25
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		—		—	$	26,493,000	$	26,493,000

Total	$	26,493,000		—		—	$	26,493,000	$	26,493,000


	As of December 31, 2014
	Fair Value Measurements
	Carrying Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the year ended December 31, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000	)
Change in fair value of warrant liability		27,873,000

Balance – December 31, 2015	$	26,493,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company’s common stock, the volatility of the Company’s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company’s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.

Capital Stock

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Text Block [Abstract]

Capital Stock

NOTE 9: CAPITAL STOCK

2016 Share Transactions

Management Compensation

In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, Dr. Wilson was awarded 0.3 million fully vested common shares at consummation of the agreement. The Company recorded an obligation to deliver the shares of $0.2 million based on the fair value of the Common stock at December 31, 2015. The Company issued the shares in March 2016 and reclassified the accrued liability to stockholders’ equity (deficit).

Consulting arrangements

In March 2016, the Company issued 0.1 million common shares as part of consulting agreements from 2015. The fair value of the common stock of approximately $0.1 million was recognized as stock-based compensation in general and administrative expense.

NOTE 8:

CAPITAL STOCK

Stock Split and increase in authorized shares

On February 18, 2014, the Company completed a reverse stock split thereby issuing 1 new share for each 100 outstanding shares of the Company’s common stock and amended the Company’s Articles of Incorporation to increase the authorized shares of common stock from 150,000,000 shares of common stock to 500,000,000 shares.

Share Capital

Series A Convertible Preferred Stock

The Company has designated 1,250,000 Series A Convertible preferred shares (Series A) par value $0.001. Each share of Series A was automatically converted into five shares of the Company’s common stock upon the occurrence of the 1:100 reverse stock split.

Series B Convertible Preferred Stock

The Company has designated 1,500,000 Series B Convertible preferred shares (Series B), par value $0.001. The terms of the Series B are as follows:

•

rank pari passu to the common stock with respect to rights on liquidation, winding up and dissolution;

•

have no dividend rights except as may be declared by the Board in its sole and absolute discretion;

•

shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock; and

•

shall automatically convert into seven (7) shares of common upon the occurrence of a 1:100 reverse stock split.

There are no shares outstanding under preferred shares as of December 31, 2015.

2015 Share Transactions

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s common stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants and pay a 7% finders fee on gross proceeds from the sale of securities.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s common stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants and pay a 3.5% finders fee on gross proceeds from the sale of securities.

Initial Fair Value of Warrants Issued

Pursuant to ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity, the common stock purchase warrants are classified as a derivative liability as the Company cannot control their ability to gross settle the financial instruments with registered securities. The fair value of the warrants issued pursuant to the January and March 2015 stock purchase agreement was $9,313,000. The weighted average inputs include contractual term of 5.0 years, volatility of 158% and risk free rate of 1.2%.

May 2015 Restructuring Agreement

In May 2015, the Company entered into a restructuring agreement with the investors of the January 2015 and March 2015 private placements, where:

•

The exercise price of the Series A warrants was changed from $1.50 per warrant to $0.10 per warrant,

•

The exercise price of Series B warrants was changed from $0.40 per warrant to $0.20 per warrant,

•

Each warrant of Series B existing prior to the restructuring agreement was replaced with two warrants of such series,

•

The exercise price of the Series C warrants was changed from $1.00 per warrant to $0.50 per warrant, and

•

Each warrant of Series C existing prior to the restructuring agreement was replaced with two warrants of such series.

As a result of the restructuring agreement, the Company issued an additional 12,320,000 Series B warrants and 12,320,000 Series C Warrants. The fair value of the warrants issued pursuant to the May 2015 restructuring agreement was $6,133,000. The weighted average inputs include contractual term of 2.46 years, volatility of 141% and risk free rate of 1.5%.

Management Compensation

In November, 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, the Company granted Dr. Wilson 315,000 shares of unregistered common stock, fully vested. As of December 31, 2015, the shares have not been issued. Accordingly, the fair value of the common stock of approximately $191,000 was accounted for as an accrued liability.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		4.30
Exercised		(37,079,990	)		0.25		—
Extinguished or expired		(203,905	)		2.39		—

Balance, December 31, 2015		52,106,497		$	0.74		4.24

During the year ended December 31, 2015, a warrant holder exercised 4,820,000 of Series A warrants at $0.10 per warrant for a total of $482,000.

During the year ended December 31, 2015, warrant holders exercised 24,639,995 of Series B warrants at $0.20 per warrant for a total of $4,928,000.

During the year ended December 31, 2015, warrant holders exercised 7,620,000 of Series C warrants at $0.50 per warrant for a total of $3,810,000.

The fair value of derivative liabilities associated with these warrants in the amount of $16,835,000 were credited to additional paid-in capital.

Stock Compensation Plan

On March 19, 2014, the Company adopted the 2014 Omnibus Stock Option Plan (“2014 Plan”). The 2014 Plan was amended in February 2015 to provide for grants to consultants, and again in November 2015 to (i) increase the number of shares reserved for issuance under the Plan by 5.0 million shares to 7.0 million shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors.

Share purchase options

A summary of the Company’s stock options as of December 31, 2015 and 2014 and changes during the years is presented below:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Intrinsic Value
Outstanding at January 1, 2014		65,430			18.00		5.04	$	—
Issued		—			—		—		—
Cancelled/Forfeited		—			—		—		—

Outstanding at January 1, 2015		65,430			18.00		4.04		—
Issued		3,540,000			0.55		4.39		—
Cancelled/Forfeited		(21,280	)		17.00		—		—

Outstanding at December 31, 2015		3,584,150		$	0.77		9.69	$	177,000

Exercisable at December 31, 2015		1,987,000		$	0.92		9.59	$	132,000

The following weighted average assumptions were used for the Black-Scholes option-pricing model to value stock options granted in 2015:


		2015
Expected life of options in years		9.08
Weighted-average volatility		230%
Risk-free rate		2.10%
Expected dividend rate		0%

Stock based compensation costs of $945,000 are expected to be recognized over the next 1.86 years.

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 9:

INCOME TAXES

The company has no income tax expense due to operating losses incurred for the years ended December 31, 2015 and 2014. Approximately $1.6 million in non-qualified stock options were cancelled during 2015 due to terminations that resulted in a reversal of the deferred tax asset of approximately $0.52 million. The cancellations did not result in a book income for December 31, 2015.

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2015 and 2014 are as follows:


	Year Ended December 31, 2015			Year Ended December 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$	8,359,000		$	10,433,000
Stock-based compensation		1,897,000			1,871,000
License agreements		268,000			—
Research and development		117,000			—
Technology licensing fee		185,000			167,000

Total deferred tax assets		10,826,000			12,471,000
Valuation allowance		(10,826,000	)		(12,471,000	)

Deferred tax assets, net of valuation allowance	$	—		$	—

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2015 and 2014. The valuation allowance decreased by $1.6 million as of December 31, 2015. The Company has research and development tax credit carryforwards of $117,000 to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2029.

The Company has approximately $24,123,000 of federal and $4,336,000 of state NOLs that may be available to offset future taxable income, if any. The federal net operating loss carryforwards, if not utilized, will expire between 2029 and 2035. The state net operating loss carryforwards, if not utilized, will expire in 2035.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

For the years ended December 31, 2015 and 2014, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:


	Year Ended December 31, 2015			Year Ended December 31, 2014
U. S. federal statutory rate	$	(11,582,000	)	$	(10,449,000	)
State taxes, net of federal benefit	$	(199,000	)		—

Permanent differences
- Non-cash loss on extinguishment of debt		—			9,122,000
- Change in fair value of derivative liabilities		9,477,000			—
- Write off of net operating loss		3,591,000			—
- Other permanent differences		12,000			62,000
Change in valuation allowance		(1,645,000	)		1,265,000
Other		346,000			—

Income tax provision (benefit)	$	—		$	—

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2015 and 2014, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2015 and 2014. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.

Significant Accounting Policies (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Accounting Policies [Abstract]

Recent accounting pronouncement

Recent accounting pronouncement

Recently Issued Accounting Pronouncements

Basis of Presentation

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Fair Value Measurements

Fair Value Measurements

•

Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

•

Prior Period Reclassifications

Prior Period Reclassifications

Stock-Based Compensation

Stock-Based Compensation

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Research and Development Costs

Research and Development Costs

Income Taxes

Income Taxes

Derivative Liability

Derivative Liability

Loss per Common Share

Loss per Common Share

Derivative Liability - Warrants and Derivative Liability - Conversion Option (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Text Block [Abstract]

Valuation Methodology


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2016			For the Quarter Ending March 31, 2015
Exercise price	$	0.70		$	0.98
Contractual term (years)		4.00			4.00
Volatility (annual)		150.00	%		158.00	%
Risk-free rate		1.05	%		1.00	%
Dividend yield (per share)		0	%		0	%


Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Year Ending December 31, 2015			For the Year Ending December 31, 2014
Strike price	$	0.74		$	10.70
Volatility (annual)		155	%		166	%
Risk-free rate		1.8	%		1.00	%
Contractual term (years)		4.2			2. 25
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of March 31, 2016
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	29,489,000		—		—	$	29,489,000	$	29,489,000

Total	$	29,489,000		—		—	$	29,489,000	$	29,489,000


	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		—		—	$	26,493,000	$	26,493,000

Total	$	26,493,000		—		—	$	26,493,000	$	26,493,000

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		—		—	$	26,493,000	$	26,493,000

Total	$	26,493,000		—		—	$	26,493,000	$	26,493,000


	As of December 31, 2014
	Fair Value Measurements
	Carrying Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2016:


	Derivative liability –warrants
Balance – January 1, 2016	$	26,493,000
Change in fair value of warrant liability		2,996,000

Balance – March 31, 2016	$	29,489,000

The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000	)
Change in fair value of warrant liability		27,873,000

Balance – December 31, 2015	$	26,493,000

Capital Stock (Tables)

12 Months Ended

Dec. 31, 2015

Text Block [Abstract]

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		4.30
Exercised		(37,079,990	)		0.25		—
Extinguished or expired		(203,905	)		2.39		—

Balance, December 31, 2015		52,106,497		$	0.74		4.24

Share Purchase Options

A summary of the Company’s stock options as of December 31, 2015 and 2014 and changes during the years is presented below:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Intrinsic Value
Outstanding at January 1, 2014		65,430			18.00		5.04	$	—
Issued		—			—		—		—
Cancelled/Forfeited		—			—		—		—

Outstanding at January 1, 2015		65,430			18.00		4.04		—
Issued		3,540,000			0.55		4.39		—
Cancelled/Forfeited		(21,280	)		17.00		—		—

Outstanding at December 31, 2015		3,584,150		$	0.77		9.69	$	177,000

Exercisable at December 31, 2015		1,987,000		$	0.92		9.59	$	132,000

Weighted Average Assumptions

The following weighted average assumptions were used for the Black-Scholes option-pricing model to value stock options granted in 2015:


		2015
Expected life of options in years		9.08
Weighted-average volatility		230%
Risk-free rate		2.10%
Expected dividend rate		0%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Capital Stock - Additional Information (Detail)		1 Months Ended				3 Months Ended	12 Months Ended
Capital Stock - Additional Information (Detail)	Feb. 18, 2014 shares	Nov. 30, 2015 shares	May 31, 2015 $ / shares	Mar. 31, 2015 USD ($) $ / Equity shares	Jan. 31, 2015 USD ($) $ / shares $ / Equity shares	Mar. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) Vote / shares $ / shares shares	Dec. 31, 2014 $ / shares shares	May 19, 2014 shares	Feb. 17, 2014 shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $							$ 191,000
Reverse stock split	100
Common stock authorized	500,000,000					500,000,000	500,000,000	500,000,000		150,000,000
Preferred stock par value						5,000,000	5,000,000	5,000,000
Preferred stock par value \| $ / shares						$ 0.001	$ 0.001	$ 0.001
Preferred stock outstanding							0
Units issued				5,000,000
Sales price per unit \| $ / Equity				0.20
Aggregate purchase price \| $				$ 950,000
Finders fee and issuance costs \| $				$ 50,000
Number of common stock included in equity unit				1
Number of warrants issued							52,106,497	2,659,417
Number of warrants exercised							37,079,990
Proceeds from warrants exercised \| $							$ 9,219,998
Stock based compensation cost \| $							$ 945,000
Share based compensation recognized period							1 year 10 months 10 days
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $						$ 100,000
Common shares issued						100,000
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Shares granted		300,000
Fair value of common stock \| $							$ 200,000
Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants				1
Exercise price of warrants \| $ / shares			$ 0.10				$ 0.10
Number of warrants exercised							4,820,000
Proceeds from warrants exercised \| $							$ 482,000
Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants				1
Exercise price of warrants \| $ / shares			$ 0.20				$ 0.20
Replacement of warrants			2.00%
Number of warrants issued							12,320,000
Number of warrants exercised							24,639,995
Proceeds from warrants exercised \| $							$ 4,928,000
Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants				1
Exercise price of warrants \| $ / shares			$ 0.50				$ 0.50
Replacement of warrants			2.00%
Number of warrants issued							12,320,000
Number of warrants exercised							7,620,000
Proceeds from warrants exercised \| $							$ 3,810,000
Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants				1
Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants				1
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of warrant or right, number of securities called by warrants or rights				125,000	366,000
Finders fee, Percentage				3.50%	7.00%
Series A B and C Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Derivative liabilities \| $							16,835,000
2014 Omnibus Stock Option Plan [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of shares reserved for issuance		7,000,000							5,000,000
January and March 2015 Share Purchase Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Derivative liabilities \| $							$ 9,313,000
Contractual term (years)							5 years
Volatility (annual)							158.00%
Risk-free rate							1.20%
Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Shares granted		315,000
May 2015 Restructuring [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Derivative liabilities \| $							$ 6,133,000
Contractual term (years)							2 years 5 months 16 days
Volatility (annual)							141.00%
Risk-free rate							1.50%
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Units issued					7,320,000
Sales price per unit \| $ / Equity					0.20
Aggregate purchase price \| $					$ 1,250,000
Finders fee and issuance costs \| $					$ 214,000
Number of common stock included in equity unit					1
Private Placement [Member] \| Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1
Exercise price of warrants \| $ / shares					$ 1.50
Warrant expiration period					5 years
Private Placement [Member] \| Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1
Exercise price of warrants \| $ / shares					$ 0.40
Warrant expiration period					6 months
Private Placement [Member] \| Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1
Exercise price of warrants \| $ / shares					$ 1.00
Warrant expiration period					5 years
Private Placement [Member] \| Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1
Exercise price of warrants \| $ / shares					$ 0.75
Warrant expiration period					5 years
Private Placement [Member] \| Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1
Exercise price of warrants \| $ / shares					$ 1.25
Warrant expiration period					5 years
Series B Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred stock par value						1,500,000	1,500,000	1,500,000
Preferred stock par value \| $ / shares						$ 0.001	$ 0.001	$ 0.001
Conversion of shares into common stock							7
Reverse stock split							1100 reverse stock split
Voting right \| Vote / shares							1,000
Preferred stock outstanding						0	0	0
Series A Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred stock par value						1,250,000	1,250,000	1,250,000
Preferred stock par value \| $ / shares						$ 0.001	$ 0.001	$ 0.001
Conversion of shares into common stock							5
Reverse stock split							1100 reverse stock split
Preferred stock outstanding						0	0	0

Capital Stock - Share Purchase Options (Detail) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning Balance	65,430	65,430
Number of Options Outstanding, Issued	3,540,000
Number of Options Outstanding, Cancelled/Forfeited	(21,280)
Number of Options Outstanding, Ending Balance	3,584,150	65,430	65,430
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 18.00	$ 18.00
Number of Options Exercisable, Ending Balance	1,987,000
Weighted Average Exercise Price, Issued	$ 0.55
Weighted Average Exercise Price, Cancelled/Forfeited	17.00
Weighted Average Exercise Price Outstanding, Ending Balance	0.77	$ 18.00	$ 18.00
Weighted Average Exercise Price Exercisable, Ending Balance	$ 0.92
Weighted Average Remaining Life, Options Issued	4 years 4 months 21 days
Weighted Average Remaining Life, Outstanding	9 years 8 months 9 days	4 years 15 days	5 years 15 days
Weighted Average Remaining Life, Exercisable	9 years 7 months 2 days
Intrinsic Value, Issued	$ 0
Intrinsic Value Outstanding	$ 177,000
Intrinsic Value, Exercisable	$ 132,000

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax [Line Items]
Income tax expense	$ 0	$ 0
Non-qualified stock options cancelled, Value	1,600,000
Reversal of deferred tax assets	520,000
Valuation allowance decreased amount	(1,645,000)	1,265,000
Research and development tax credit carryforwards	$ 117,000
Tax credit carryforwards expiration period	2029
Federal net operating loss carryforwards	$ 24,123,000
State NOLs	$ 4,336,000
Tax credit carryforwards expiration year end	2035
Accrued amount for payment of interest and penalties	$ 0	0
Unrecognized tax benefits	$ 0	$ 0
Research and Development Tax Credit Carryforwards [Member]
Income Tax [Line Items]
Tax credit carryforwards expiration period	2029

Income Taxes - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 8,359,000	$ 10,433,000
Stock-based compensation	1,897,000	1,871,000
License agreements	268,000
Research and development	117,000
Technology licensing fee	185,000	167,000
Total deferred tax assets	10,826,000	12,471,000
Valuation allowance	(10,826,000)	(12,471,000)
Deferred tax assets, net of valuation allowance	$ 0	$ 0

Income Taxes - Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U. S. federal statutory rate	$ (11,582,000)	$ (10,449,000)
State taxes, net of federal benefit	(199,000)
Permanent differences
Permanent differences- Non-cash loss on extinguishment of debt		9,122,000
Permanent differences- Change in fair value of derivative liabilities	9,477,000
Permanent differences- Write off of net operating loss	3,591,000
Permanent differences- Other permanent differences	12,000	62,000
Change in valuation allowance	(1,645,000)	1,265,000
Other	346,000
Income tax provision (benefit)	$ 0	$ 0

Liquidity and Financial Condition	3 Months Ended
Liquidity and Financial Condition	Mar. 31, 2016
Text Block [Abstract]
Liquidity and Financial Condition	NOTE 3: LIQUIDITY AND FINANCIAL CONDITION The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of March 31, 2016, the Company had cash and cash equivalents of approximately $5,722,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Liquidity and Financial Condition - Additional Information (Detail)	Mar. 31, 2016 USD ($)
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 5,722,000

Potentially Dilutive Securities - Net Loss per Share (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Common stock options	3,584,000	65,000	3,584,150	65,430
Common stock warrants - equity treatment	2,556,000	2,549,000	2,548,632	2,556,133
Common stock warrants - liability treatment	49,528,000	62,194,000	49,557,865	103,284
Excluded potentially dilutive securities	55,668,000	64,808,000	55,690,647	2,724,847

Promissory Notes - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 30,000	$ 29,942
Promissory Notes Due in 2012 [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%	10.00%
As Previously Reported [Member]
Debt Instrument [Line Items]
Outstanding promissory notes			$ 30,000

Promissory Note, Related Party - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Outstanding promissory notes	$ 23,000	$ 23,000	$ 23,000
Officer and Director [Member]
Related Party Transaction [Line Items]
Outstanding promissory notes	23,000	23,000	$ 23,000
Amount of promissory notes interest charges	$ 0	$ 0

Derivative Liability - Warrants and Derivative Liability - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 29,489,000	$ 26,493,000	$ 9,000
Total	29,489,000	26,493,000	9,000
Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,489,000	26,493,000	9,000
Total	29,489,000	26,493,000	9,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,489,000	26,493,000
Total	$ 29,489,000	$ 26,493,000
Carrying Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants			9,000
Total			$ 9,000

Derivative Liability - Warrants and Derivative Liability - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Balance	$ 26,493,000	$ 9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000)
Change in fair value of warrant liability	2,996,000	27,873,000
Balance	$ 29,489,000	$ 26,493,000

Nature of Operations - Additional Information (Detail)	12 Months Ended
Nature of Operations - Additional Information (Detail)	Dec. 31, 2015 Patient
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of ovarian cancer patients	30,000
Percentage of breast cancers	50.00%
Percentage of ovarian cancers	95.00%

Capital Stock - Share Purchase Warrants (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Number of Warrants, Beginning balance	2,659,417
Number of Warrants, Issued	86,730,975
Number of Warrants, Exercised	(37,079,990)
Number of Warrants, Extinguished or expired	(203,905)
Number of Warrants, Ending balance	52,106,497	2,659,417
Weighted Average Exercise Price, Beginning Balance	$ 1.83
Weighted Average Exercise Price, Issued	0.54
Weighted Average Exercise Price, Exercised	0.25
Weighted Average Exercise Price, Extinguished or expired	2.39
Weighted Average Exercise Price, Ending Balance	$ 0.74	$ 1.83
Weighted Average Remaining Life, Warrants Issued	4 years 3 months 18 days
Weighted Average Remaining Life	4 years 2 months 27 days	4 years 1 month 24 days

Capital Stock - Weighted Average Assumptions (Detail)	12 Months Ended
Capital Stock - Weighted Average Assumptions (Detail)	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life of options in years	9 years 29 days
Weighted-average volatility	230.00%
Risk-free rate	2.10%
Expected dividend rate	0.00%

Contingencies and Commitments - Additional Information (Detail) - USD ($)			12 Months Ended
	Jun. 21, 2016	Mar. 21, 2016	Dec. 31, 2015
License and Assignment Commitment [Member]
Commitment And Contingencies [Line Items]
Upfront license fee payments		$ 100,000
Payment of annual license maintenance fees			$ 50,000
Payment of annual license maintenance fees			$ 50,000
Percentage of royalty on sales of the licensed product			6.00%
Scenario, Forecast [Member] \| License and Assignment Commitment [Member]
Commitment And Contingencies [Line Items]
Upfront license fee payments	$ 350,000
Office Property Lease Agreement [Member]
Commitment And Contingencies [Line Items]
Term of lease			1 year
Lease expiration date			Jul. 31, 2016
Minimum rental payments			$ 17,500